-
公开(公告)号：US20180200328A1
公开(公告)日：2018-07-19
申请号：US15906481
申请日：2018-02-27
申请人： Leidos, Inc.
IPC分类号： A61K38/10 , A61K39/39 , A61K39/015 , A61K38/16 , A61K39/00 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00
CPC分类号： A61K38/10 , A01K2227/105 , A01K2267/0331 , A01K2267/0337 , A61K35/17 , A61K38/16 , A61K38/19 , A61K39/0011 , A61K39/015 , A61K39/39 , A61K45/06 , A61K48/00 , A61P31/20 , A61P33/06 , A61P35/04 , A61P37/04 , C07K7/08 , C07K14/00
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US10799581B2
公开(公告)日：2020-10-13
申请号：US15908861
申请日：2018-03-01
申请人： Leidos, Inc.
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：US10799555B2
公开(公告)日：2020-10-13
申请号：US15906481
申请日：2018-02-27
申请人： Leidos, Inc.
IPC分类号： A61K38/10 , A61K39/015 , A61K38/16 , A61K39/00 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00 , A61K39/39 , A61K48/00
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US10098950B2
公开(公告)日：2018-10-16
申请号：US15705333
申请日：2017-09-15
申请人： Leidos, Inc.
IPC分类号： A61K6/00 , A61K39/00 , A61K39/002 , A61K39/015 , A61K39/395 , A61K45/00 , A61K45/06 , C07K1/00 , C07K16/00 , C07K16/18 , C07K16/20 , A61K39/39 , A61K38/16 , A61K38/10 , C07K7/08
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：US11793856B2
公开(公告)日：2023-10-24
申请号：US17015658
申请日：2020-09-09
申请人： Leidos, Inc.
IPC分类号： A61K38/10 , A61K39/015 , A61K38/16 , A61K39/00 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00 , A61K39/39 , A61K48/00
CPC分类号： A61K38/10 , A61K35/17 , A61K38/16 , A61K38/19 , A61K39/0011 , A61K39/015 , A61K39/39 , A61K45/06 , A61P31/20 , A61P33/06 , A61P35/04 , A61P37/04 , C07K7/08 , C07K14/00 , A01K2227/105 , A01K2267/0331 , A01K2267/0337 , A61K48/00
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US20180185474A1
公开(公告)日：2018-07-05
申请号：US15908861
申请日：2018-03-01
申请人： Leidos, Inc.
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：US20180071385A1
公开(公告)日：2018-03-15
申请号：US15705333
申请日：2017-09-15
申请人： Leidos, Inc.
IPC分类号： A61K39/39 , A61K38/16 , A61K39/00 , A61K39/015
CPC分类号： A61K39/39 , A61K38/10 , A61K38/16 , A61K39/0011 , A61K39/015 , A61K2039/55516 , C07K7/08
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：US20240075131A1
公开(公告)日：2024-03-07
申请号：US18388036
申请日：2023-11-08
申请人： Leidos, Inc.
CPC分类号： A61K39/39 , A61K38/10 , A61K38/16 , A61K39/0011 , A61K39/015 , C07K7/08 , A61K2039/55516 , Y02A50/30
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：US20230414703A1
公开(公告)日：2023-12-28
申请号：US18204545
申请日：2023-06-01
申请人： Leidos, Inc.
IPC分类号： A61K38/10 , A61K39/015 , A61K38/16 , A61K39/00 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00 , A61K39/39
CPC分类号： A61K38/10 , A61K39/015 , A61K38/16 , A61K39/0011 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00 , A61K39/39 , A61K48/00
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US20210000948A1
公开(公告)日：2021-01-07
申请号：US17026447
申请日：2020-09-21
申请人： Leidos, Inc.
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.012 秒)
